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A B S T R A C T
Nausea is a subjective sensation, which often acts as a signal that emesis is imminent. It is a wide-
spread problem that occurs as a clinical sign of disease or as an adverse effect of a drug therapy or surgical
procedure. The mechanisms of nausea are complex and the neural pathways are currently poorly un-
derstood. This review summarises the current knowledge of nausea mechanisms, the available animal
models for nausea research and the anti-nausea properties of commercially available anti-emetic drugs.
The review also presents subjective assessment and scoring of nausea. A better understanding of the un-
derlying mechanisms of nausea might reveal potential clinically useful biomarkers for objective
measurement of nausea in species of veterinary interest.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Introduction
Nausea is an unpleasant subjective experience, colloquially
deﬁned as feeling queasy or sick to the stomach (Koch, 1995). The
experience of nausea is linked with the urge to vomit (Jenns, 1994;
Kowalski et al., 2006; Holmes et al., 2009), but nausea does not
always result in emesis (Shelke et al., 2004) and is reported by human
patients to be a worse experience and more disabling than the act
of vomiting itself.
The origins and mechanisms of nausea have yet to be fully elu-
cidated, but it continues to be a common problem in both human
and veterinary medicine. Nausea is a frequent indication of disease
and an adverse effect of many drug therapies; it is reported in human
patients receiving cancer chemotherapy as the most distressing side
effect (Morrow et al., 2002b). This could also be the case in veter-
inary medicine but, as nausea is a subjective sensation reported by
human patients, its detection in veterinary species relies on obser-
vation of signs that are the animal’s response to this sensation. These
are variably expressed depending on individual susceptibility, extent
of disease and drug treatments administered. By analogy to pain
(Stern et al., 2011), nausea has a protective function and could there-
fore be perceived by animals (Schwartz et al., 1996). Humans describe
nausea as a multidimensional experience including physical, emo-
tional and psychological components (Muth et al., 1996), making
it challenging to quantify accurately in non-verbal species. Lack of
an objective measure of nausea greatly impedes the assessment of
nausea in veterinary practice. Current behavioural assessments are
subjective, entirely based on the observer’s opinion and are, there-
fore, liable to large inter-observer variation. A better understanding
of the mechanisms that lead to the sensation of nausea might reveal
potential clinically useful biomarkers for nausea.
Our inability to positively identify animals experiencing nausea
in clinical practice with certainty makes it diﬃcult to understand
the extent of the phenomenon and its clinical consequences for vet-
erinary patients. It could be speculated that the experience of nausea
in response to drugs and disease states leads to subtle signs, which
are often missed, by veterinarians, veterinary technicians and pet
owners. Nausea could underlie the inappetence that aﬄicts our vet-
erinary patients under a number of circumstances. Thus, a more
complete understanding of nausea in veterinary patients is impor-
tant and the goal of ﬁnding a suitable biomarker of nausea is highly
desirable. Such a biomarker would help us to recognise those animals
affected by nausea and could be used to assess the response of vet-
erinary patients to anti-nausea medications, ultimately allowing us
to improve the quality of life of the animals in our care.
Mechanism of emesis
Causes of emesis are numerous but all initiate the emetic reﬂex
universally coordinated by the vomiting centre (VC) located in the
brainstem (Elwood et al., 2010). The VC can receive pro-emetic
stimuli from the following sources: chemical emetogens in the cir-
culation via the area postrema (also known as the chemoreceptor
trigger zone), abdominal vagal and glossopharyngeal afferents, the
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central nervous system, and the vestibular system (Sanger and
Andrews, 2006). On receiving stimuli which surpass the emetic
threshold, the VC acts as a central pattern generator, producing con-
trolled stimulation of output nuclei located in the brainstem to
induce the emetic reﬂex (Hornby, 2001).
Exploration of nausea mechanisms
Nausea, much like pain, is a perceptual experience involving not
only a physiological but also an affective response (Schwartz et al.,
1996). Nausea can be induced by an emotional state such as fear
or anticipation. Anxiety levels in human patients prior to cancer che-
motherapy treatment are predictive of chemotherapy-induced nausea
and vomiting (CINV; Yap et al., 2012). In our experience, dogs ex-
perience anticipatory nausea with repeated pairing of a speciﬁc
context to emetic stimuli. However, the ability of animals to expe-
rience nausea in the same way as humans is a topic for debate, due
to their inability to verbalise the experience. While we cannot know
the emotional response of animals to nausea, it is a protective phys-
iological response and is undoubtedly aversive in order to discourage
future exposure to potentially damaging scenarios or toxins.
Identiﬁcation of nausea mechanisms in animals is complicated
by its subjective nature and the inability of animals to self-report
the sensation of nausea experienced. Unlike studies of emesis, which
can be carried out in anaesthetised animal models, nausea studies
must be carried out in conscious subjects.
Emesis is controlled in the brainstem but the sensation of nausea
is thought to arise from the activation of cortical structures in-
volved in conscious perception (Sanger and Andrews, 2006; Horn,
2008; Holmes et al., 2009). Rostral projections from emetic regions
of the brainstem or direct input from the vestibular systemmay stim-
ulate the cortical nausea centre (Sanger and Andrews, 2006).
Prodromal signs of vomiting, such as salivation, cutaneous vasocon-
striction and tachycardia, controlled by the autonomic nervous system,
are activated at the same time as the sensation of nausea is re-
ported. These add to the overall unpleasantness of nausea (Morrow
et al., 2002b; Sanger and Andrews, 2006). The onset of nausea has
been linked to changes in the levels of hormones controlled by the
HPA axis, such as arginine vasopressin (AVP; Cubeddu et al., 1990c;
Kim et al., 1997) and cortisol (Fredrikson et al., 1992; Morrow et al.,
2002a). The release and relevance of these hormones in relation to
nausea are discussed in more detail elsewhere in this review.
A variety of experimental techniques have been employed in an
attempt to locate the area of the cortex responsible for the genesis
of nausea sensation. Electroencephalographic recordings of human
volunteers experiencing motion sickness identiﬁed activity in the
temporo-frontal region, which resembled that of a partial seizure
(Chelen et al., 1993). Magnetic source imaging (MSI) has been em-
ployed in the study of nausea, as it combines functional data from
magnetoencephalography and the structural data frommagnetic res-
onance imaging (MRI). MSI has demonstrated increased neuronal
activation in the inferior frontal gyrus, which correlated with self-
reported nausea scores in human volunteers following vestibular
stimulation or the ingestion of syrup of ipecac (Miller et al., 1996).
Horn et al. (2007) studied the activity of forebrain areas following
intraperitoneal administration of cisplatin in rats. In these rats, c-fos
expression, a marker of neuronal activity, was signiﬁcantly in-
creased in both the central amygdala and the bed nucleus of the
stria terminalis, which implicates these areas in conscious percep-
tion of nausea (Horn et al., 2007).
A study by Napadow et al. (2013) suggests that the brain regions
involved in the evolution of nausea are numerous. Motion sick-
ness was induced in human volunteers by the use of an optokinetic
drum and functional magnetic resonance imaging (fMRI) was con-
ducted while they self-reported nausea scores. Increased activity
was recorded in the left amygdala, the ventral putamen and the pu-
tative locus coeruleus prior to the subject reporting an increasing
nausea score (i.e. these two events were associated, but there was
a time lag between them). Increased nausea was also associatedwith
increased activity in the following cortical regions: insula, cingu-
late, somatosensory, orbitofrontal, prefrontal and premotor cortices
and in subcortical structures including the putamen, nucleus
accumbens and ventral tegmental area. These brain regions en-
compass areas involvedwith fear, emotion and stress (Napadow et al.,
2013), which are involved with the perception of nausea in humans.
Manifestations of nausea in experimental models and in
clinical settings
Rats are a non-emetic species, as their nibbling style of food intake
allows for food to be sampled and avoided should a nausea-like state
occur (Andrews and Horn, 2006). Despite their inability to vomit,
rats have been used extensively to study of the neurochemistry of
nausea using a number of behavioural models. Conditioned taste
avoidance (CTA) uses this innate nibbling behaviour as a measure
of nausea. If a novel ﬂavour (e.g. saccharin) is paired with an
emetogen (e.g. lithium chloride), avoidance of the novel ﬂavour can
then be tested (Yamamoto et al., 1995). CTA is attenuated by lesions
to the area postrema (Ritter et al., 1980) and is reversed by some
antiemetic agents (Coil et al., 1978); however, CTA is also induced
when the ﬂavour is paired with non-nausiogenic drugs which have
reinforcing properties such as amphetamine or LSD. This suggests
that CTAmeasures the rat’s defensive avoidance of any ﬂavour paired
to an altered physiological state rather than speciﬁcally measur-
ing a nausea-like response.
Conditioned gaping in rats mimics the orofacial reactions seen
during the emetic reﬂex in emetic species. This has been argued to
provide a more robust measure for nausea than CTA (Limebeer et al.,
2006; Parker and Limebeer, 2006). Gaping appears to be selec-
tively induced by emetic drugs (Parker, 1998) and is reversed by
the anti-emetics ondansetron (Limebeer and Parker, 2000) and Δ9-
tetrahydrocannabinol (Δ 9-THC) (Limebeer and Parker, 1999).
Although ratmodels have been useful in identifying the neurotrans-
mitters involved in nausea pathways, they are better described as
measuring a ‘nausea-like’ response, as the existence of the sensation
of nausea in non-emetic species is uncertain. In this respect, the term
nausiception could be coined from nausia, the Greek origin of the
nausea. By analogy to nociception, nausiception would be used to de-
scribe the afferent neural response to emetic stimuli but would not
encompass the emotional elements of nausea, in much the sameway
as nociception is the neural component of pain (Table 1; Le Bars et al.,
2001). Nocifensive behaviours are observed after nociceptive stimu-
lation (Fan et al., 1995) and are the defensive response associatedwith
protection against the insult. Similarly, nausifensive behaviours occur
as a defensive response to anausiceptive stimulus. In rodents, thiswould
describe the conditioned gaping behaviour and in other species the pro-
dromal responses (salivation, sweating, changes in pallor) associated
with nausea that precede the emetic reﬂex. Pain and nausea are only
experienced in the conscious subject or animal but, like nociception,
nausiception couldbe evaluated in the anaesthetised animal by themea-
surement of neuronal activity.
In emetic animal species such as the dog, cat, ferret and Suncus
murinus (house musk shrew), nausea and emesis can be induced by
Table 1
Characteristics of nociceptive and posited nausiceptive responses.
Sensation Requires
conscious
subject
Neural encoding
and ascending
processing
Elicited
protective
behaviours
Pain Yes Nociception Nocifensive behaviours
Nausea Yes Nausiception Nausifensive behaviours
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a number of chemical emetogens. These emetogens act peripheral-
ly to stimulate vagal afferent ﬁbres due to 5-hydroxytryptamine (5-
HT) released in the gastrointestinal tract e.g. after the administration
of syrup of ipecac (Soderpalm et al., 2001) or centrally, by stimulat-
ing the chemoreceptor trigger zone e.g. after the administration of
apomorphine (Andrews et al., 1990). Alternatively, certain emetogens,
such as cisplatin, have both a central and peripheral action (Minami
et al., 2003). These mechanisms are clinically relevant, as therapeu-
tic agents stimulate these pathways, causing nausea and emesis as
side effects. Table 2 presents medicines that give rise to nausea and
emesis in small animals.
In species relevant to veterinary small animal practice, there is
a much greater representation of dogs than cats in nausea re-
search and reporting. A search of the literature in PubMed using the
terms ‘nausea AND (cat/s OR feline)’ returned 112 results, of which
24 were relevant after inspection of the abstracts. However, a search
for ‘nausea AND (dog/s OR canine)’ produced 219 results, of which
105 were relevant following inspection of the abstracts. This is prob-
ably because the dog is a more common laboratory species than the
cat.
Behavioural assessment of nausea
Currently, the measurement of nausea relies on the interpreta-
tion of behavioural changes that are thought to be related to nausea.
Salivation, lip licking and restlessness are most often observed
(Table 3). Behavioural change is quantiﬁed using a scoring system such
as the visual analogue scale (VAS), a 100mm line on which a mark
is made to denote perceived nausea, where 0 mm represents ‘no
nausea’ and 100mm ‘worst possible nausea’. Such a scoring system
has been utilised in dogs (de la Puente-Redondo et al., 2007) and cats
(Hickman et al., 2008) based on the following behaviours: exagger-
ated swallowing, salivation, licking lips, body posture, lethargy,
depression and restlessness. It is important that the context is taken
into account, as in isolation, or when conﬂicting conditions such as
stress or pain are present, these behaviours might not be a speciﬁc
measure of nausea. This is a highly subjective method of measure-
ment; scores are allocated by observers and there can be large
variations between observers. To limit this variation, observers should
be trained to recognise ‘nausea’ behaviours and, if practicable, the
same observer/s, blinded to treatment allocation, should be present
for all scoring in a single study (Kenward et al., 2014).
Rau et al. (2010) used a simpliﬁed VAS scoring system in dogs
consisting of a ﬁve-point scale with descriptions of behaviour. The
narrowed criteria of this system might reduce inter-observer vari-
ation, but can also result in the exclusion of pertinent ‘nausea’
behaviours, not mentioned in the description. Further drawbacks
of the VAS system are also evident in the context of a clinical study.
In a busy veterinary hospital or practice it is often not practical for
animal care staff to constantly observe canine patients, and there-
fore periods of nausea might be missed. If observations continue
in the home environment, the same problem occurs and further-
more, owners are not trained to recognise nausea behaviours. The
construction of a composite scale including weighted quantitative
behavioural changes and validated nausea biomarkers could in-
crease the objectivity and validity of nausea scoring.
Several self-reporting scales have been designed for use in
humans. Some, such as the Melzack questionnaire (Melzack et al.,
1985, inspired by theMcGill pain scale), attempt to capture themul-
tidimensional experience of nausea. Muth et al. (1996) designed a
nausea proﬁle questionnaire which recognises that nausea is prob-
ably manifested differently in each patient as a complex syndrome
with several dimensions, each of which could be measured indi-
vidually (somatic distress, gastro-intestinal distress and emotional
distress).
Neurotransmitters involved in nausea and potential
nausea biomarkers
The ideal nausea biomarker would be a speciﬁc physiological vari-
able, easily measured without bias, which is released in proportion
to the severity of nausea experienced by the animal. Such a
biomarker would be important in clinical research where there is
a need tomeasure nausea, in conditions not conducive to behavioural
measurement, and when quantifying the effect of anti-nausea treat-
ment in particular clinical settings (Table 4). While the evidence
presented below for potential nausea biomarkers is mainly based
on studies in humans, it is the opinion of the authors that these also
have the potential to be validated in animals.
Neurotransmitters and hormones involved in the sensation of
nausea are diverse and there is evidence that noradrenaline (NA),
5-HT, vasopressin and substance P all have some role in the genesis
Table 2
Stimulus or drugs associated with nausea and emesis in small animal practice.
Stimulus/drug Representative example Reference
Purgative emetogen Apomorphine, syrup of ipecac (Sedlacek et al., 2008)
Cytotoxic drugs Cisplatin, doxorubicin, methotrexate,
carboplatin
European Emesis Councila (Hahn et al., 1997; Yamakuni et al., 2000; Kristal et al., 2001;
de la Puente-Redondo et al., 2007; Rau et al., 2010; Kenward et al., 2014)
Opioids Morphine, hydromorphone (Villablanca et al., 1984; Foss et al., 1993; Hay Kraus, 2013)
Alpha-2 adrenoceptor agonists Xylazine, medetomidine (Lucot and Crampton, 1986; Vaha-Vahe, 1989; Hikasa et al., 1992; Cullen, 1996)
Antibiotics Erythromycin and other macrolides,
metronidazole, doxycycline
European Emesis Councila
Antifungal Ketoconazole (Medleau and Chalmers, 1992; Mayer et al., 2008)
Plant alkaloids Digoxin, lycorine European Emesis Councila (Kretzing et al., 2011a)
Vasopressors Vasopressin infusion (Chen et al., 2003; Tatewaki et al., 2005)
a See: http://www.emesiscouncil.com/knowledge-hub/nausea (accessed 23 September 2014).
Table 3
Canine behaviours associated with nausea. Behaviours listed in table are as ob-
served by authors during pre-clinical studies and clinical practice or as reported in
the nausea knowledge statement produced by the European Emesis Council.a
Behaviour Clinical signs
Salivation Hypersalivation, increase in swallowing
frequency, gulping, chewing movements
Gastro-intestinal disturbances Pica, belching, productive or non-productive
vomiting, defecating
Lip smacking Lip licking, licking the nose, nictation (the
action of winking)
Excitement behaviours Apprehension, restlessness, rapid breathing
Vocalisation Murmuring, groaning, whining
Withdrawal behaviours Standing with the head drooping, closing eyes,
yawning, drowsiness, lethargy and excessive
sleeping
Appetite Decreased appetite, avoidance of food bowl
a See: http://www.emesiscouncil.com/knowledge-hub/nausea (accessed 23
September 2014).
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of nausea; their potential as nausea biomarkers applicable to the
veterinary patient is discussed elsewhere in this review.
5-Hydroxytryptamine
Antagonists of the neurotransmitter 5-HT3, such as ondansetron,
constitute a major class of anti-emetics. They are highly eﬃca-
cious in the treatment of chemotherapy-induced acute emesis and
have some anti-nausea eﬃcacy, thereby implicating 5-HT in the
mechanism of nausea. A number of experiments have been carried
out in the rat to further investigate the role of 5-HT in nausea.
Reduced 5-HT availability leads to the prevention of the develop-
ment of conditioned gaping in rats (Parker et al., 2010). Pre-
treatment of rats with the selective 5-HT1A agonist, 8-OH-DPAT,
reduces 5-HT availability due to its auto-receptor function and at-
tenuates the conditioned gaping response in rats (Limebeer and
Parker, 2003). Decrease in striatal and hippocampal 5-HT follow-
ing lesions of themedian and dorsal raphe nuclei causes a signiﬁcant
decrease in conditioned gaping in rats (Limebeer et al., 2004).
Although 5-HT release and stimulation of abdominal afferent
vagal ﬁbres might be responsible for nausea and emesis, the rapid
uptake and metabolism of these compounds limit their potential
use as biomarkers. Therefore, it might be more practical to mea-
sure a stable metabolite of 5-HT in plasma or urine, such as 5-
hydroxyindoleacetic acid (5-HIAA). Urinary excretion of 5-HIAA (cor-
rected by creatinine) is signiﬁcantly increased from pre-treatment
levels in human cancer patients receiving high-dose cisplatin or
cyclophosphamide (Cubeddu et al., 1990b, 1992). Cubeddu et al.
(1990b) also reported that 5-HIAA excretion rose in parallel
to the onset of emesis; however, nausea was not recorded in this
study.
Noradrenaline
Catecholamines can play a role in the neurohumoral develop-
ment of nausea and emesis (Andrews et al., 1988). It has been
hypothesised that NA promotes 5-HT release from the gut periph-
erally, and that this could increase receptor sensitivity centrally,
facilitating emetogen detection in the area postrema (Fredrikson
et al., 1994). Alpha2-adrenoceptors have been identiﬁed in the area
postrema (Beleslin and Strbac, 1987) and are thought to be mainly
located pre-synaptically to transmit emetic signals (Japundzic-Zigon
et al., 1997). Phosphodiesterase (PDE)-4 inhibitors, such as rolipram,
which increase NA neurotransmission, cause a dose-dependent in-
crease in conditioned gaping in rats when paired with either a
speciﬁc ﬂavour or context (Rock et al., 2009). Rolipram-induced
nausea is likely to be due to triggering of noradrenergic rostral pro-
jections from the brainstem to the cortex.
Urinary NA excretion has been investigated as a marker of nausea
in humans with cancer chemotherapy-induced emesis. High pre-
treatment NA excretion is predictive of the intensity of delayed
nausea of cancer chemotherapy (Fredrikson et al., 1994). Further
studies are required to characterise changes in endogenous NA levels
in both the brain (or at least cerebrospinal ﬂuid) and plasma during
periods of nausea and emesis.
Substance P
The neurokinin1 (NK1) receptor and its endogenous ligand the
peptide neurotransmitter, substance P, have been identiﬁed as me-
diators of emetic responses. NK1 receptors have been localised in
emetic brainstem regions such as the area postrema, the solitary
nucleus, and the dorsal motor nucleus of the vagus (Watson et al.,
1995; Sanger, 2004). There is also evidence of a secondary periph-
eral role of NK1 receptors in emesis involving modulation of
abdominal vagal afferent activity (Minami et al., 2001).
Since substance P has a predominantly central action, its mea-
surement as a biomarker is problematic. Microdialysis can be used
to measure substance P concentrations in the brain (André and
Caprioli, 1995), but this method is mainly used in rodents andwould
be impractical in emetic species such as the dog.
Arginine vasopressin
Plasma arginine vasopressin (AVP) is greatly increased by emetic
stimuli with up to an 80-fold increase from baseline levels re-
ported (Rowe et al., 1979). In humans, a positive correlation between
plasma AVP increase and nausea induced by motion sickness has
been documented (Otto et al., 2006). Increased AVP levels in the
plasma have also been detected in dogs following cisplatin treat-
ment (Cubeddu et al., 1990c). Infusion of arginine vasopressin
induces nausea in humans (Kim et al., 1997) and can induce both
nausea and gastric dysrhythmias in dogs (Chen et al., 2003). Char-
acterisation of vasopressin receptor distribution and the use of
selective vasopressin antagonists should enable identiﬁcation of the
role of the vasopressin pathway in nausea. It is currently unclear
whether AVP has a role in the induction of nausea or is released
as a consequence of nausea.
There is potential for plasma AVP to be used as an objective
marker of nausea resulting from motion sickness and drug admin-
istration. AVP has the closest correlation with onset and offset of
nausea of all candidate hormones and neurotransmitters mea-
sured during acute nausea related to motion in human volunteers
(Stern et al., 2011).
Cortisol
The role of cortisol in the physiology of nausea is currently
unknown; however, corticosteroids have some anti-emetic and anti-
nausea properties in humans (Aapro and Alberts, 1981). As a result,
dexamethasone is often included as a component of anti-emetic regi-
mens for the treatment of CINV in human medicine (Roila et al.,
2010).
In human patients, night-time urinary cortisol concentrations
prior to cancer-chemotherapy were inversely related to nausea and
patients with low baseline cortisol reported signiﬁcantly higher
Table 4
Circumstances associated with nausea in veterinary clinical practice.
Recognised conditions associated with nausea in animals Recognised association with nausea in humans but lacking evidence in animals
Pancreatitis (European Emesis Councila) Pregnancy (Lacasse et al., 2008)
Uraemia (Krawiec, 1996) Diabetes-associated nausea (Koch, 1999)
Vestibular disease (Rossmeisl, 2010) and motion sickness (Conder et al., 2008) Post-operative nausea and vomiting (Koivuranta and Laara, 1998)
Drugs (see Table 2)
Hormones (vasopressin; Chen et al., 2003)
Emetogens (ipecac and apomorphine; Sedlacek et al., 2008)
a See: http://www.emesiscouncil.com/knowledge-hub/nausea (accessed 23 September 2014).
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nausea scores (Fredrikson et al., 1992). Additionally, serum corti-
sol concentrations were signiﬁcantly reduced 1 h following either
cisplatin or carboplatin/cyclophosphamide administration (Morrow
et al., 2002a). Further studies are required to fully determine the
association between cortisol concentrations and the intensity of
nausea and to elucidate the role of cortisol in the experience of
nausea.
Autonomic activity
Autonomic tone almost certainly plays a role in nausea, since the
autonomic nervous system controls many of the prodromal signs
of emesis (e.g. salivation, sweating and vasoconstriction), which are
activated simultaneously with the sensation of nausea (Morrow et al.,
2000, 2002b). Basal autonomic tone has been linked to the likeli-
hood of developing anticipatory nausea and vomiting (ANV) due
to cancer chemotherapy (Kvale et al., 1991). In this study, human
patients that developed ANV had signiﬁcantly higher sympathetic
reactivity compared to the no-ANV group. An increase in sympa-
thetic activity and a decrease in parasympathetic activity have been
associatedwithmotion sickness (Hu et al., 1991; Doweck et al., 1997).
Gastric myoelectrical activity was measured in dogs by Yu et al.
(2009), who demonstrated that the percentage of normal slowwaves
were signiﬁcantly decreased prior to and during cisplatin-induced
emesis.
It is not clear whether autonomic activity alone is nausiogenic,
or if it is part of a more complex mechanism leading to nausea. Al-
ternatively, it is possible that autonomic activation occurs as a
consequence of other nausiogenic mechanisms, rather than driving
nausea directly. Nevertheless, measuring autonomic activity through
the analysis of heart rate variability (Stern et al., 2011),
electrogastrography, or changes in skin conductivity might prove
to be useful biomarkers to detect nausea before its peak andmeasure
its intensity.
Brain imaging as a biomarker of nausea
Imaging with fMRI has facilitated non-invasive identiﬁcation of
the activation sequence of brain structures involved in the nausea
pathway (Napadow et al., 2013). Functional imaging technology is
not widely accessible for veterinary species and the utility of fMRI
in animals is limited by the fact that it must be carried out in con-
scious non-sedated subjects.
Anti-nausea potential of current and future
antiemetic treatments
In human medicine, all anti-emetic drugs have label claims that
they reduce nausea since it is accepted that, in most cases, nausea
is a prerequisite of emesis. Although there are some stimuli that
induce emesis with little nausea, the two are generally associated.
However, it is purely assumption that if a drug prevents emesis, it
will also prevent nausea. It is recognised that nausea is more dif-
ﬁcult to prevent and treat than emesis. Emesis is an all-or-nothing
event and an antiemetic drug is effective if it inhibits emetic stimuli
to such a degree that the threshold for the emetic reﬂex is not
reached. However, this could still leave the patient feeling some-
what nauseous, since nausea is a graded phenomenon i.e. one can
feel mildly, moderately or severely nauseous. This graded phenom-
enon can also be implied from observations in veterinary patients
of the frequency and severity of nausea behaviours. The under-
standing of the mechanisms and pathways through which the
sensation of nausea occurs would enable the prediction of the most
effective anti-nausea drugs.
D2 receptor antagonists
Metoclopramide, a dopamine2 (D2) and weak 5-HT3 antagonist,
is a commonly used antiemetic in veterinary medicine (Mantione
and Otto, 2005) and is effective against apomorphine and cisplatin-
induced emesis in dogs (Alphin et al., 1986). A search of the
published literature provides no evidence for the anti-nausea effects
of metoclopramide in the dog. However, in human medicine,
metoclopramide is reported to have eﬃcacy against post-operative
nausea following abdominal surgery (Davidson et al., 1979) and also
reduces the duration of cisplatin-induced nausea (Gralla et al., 1981).
5-HT3 receptor antagonists
As described earlier, 5-HT3 receptors are present on abdominal
vagal afferents and are involved in the detection of emetogens in
the gastrointestinal tract. Five-HT receptors also have a central role
in emesis. Many types of 5-HT3 antagonists are commercially avail-
able as antiemetics, and all use the suﬃx ‘setron’ e.g. ondanestron,
granisetron or tropisetron. Of these, ondansetron is the most widely
used and in dogs as in humans; it is eﬃcacious against acute emesis
but not delayed emesis occurring from 1 to 3 days following the
administration of chemotherapy (Yamakuni et al., 2000).
Like metoclopramide, the anti-nausea effect of ondansetron is
well documented in human patients but less so in veterinary species.
Ondansetron has been shown to signiﬁcantly reduce nausea induced
by anaesthesia (Leeser and Lip, 1991), cyclophosphamide (Cubeddu
et al., 1990a) and cisplatin (Cubeddu et al., 1990b) in humans.
Ondansetron delayed emesis and signiﬁcantly decreased nausea
scores compared with placebo in Beagle dogs administered the daf-
fodil alkaloid lycorine by IV injection (Kretzing et al., 2011b). When
administered to cats with chronic kidney disease, mirtazapine, a
tetracyclic antidepressant with activity as a 5-HT3 antagonist, had
antiemetic effects and increased appetite and activity, possibly sug-
gesting an anti-nausea action. However, nausea was not speciﬁcally
measured in this study (Quimby and Lunn, 2013).
NK1 receptor antagonists
Aprepitant was the ﬁrst drug in this class, approved for human
use in 2003, to treat chemotherapy-induced and post-operative
nausea and vomiting. Aprepitant signiﬁcantly increased the number
of patients that experienced no nausea or no signiﬁcant nausea
(Poli-Bigelli et al., 2003; Diemunsch et al., 2007).
The NK1 antagonist maropitant is an anti-emetic speciﬁcally de-
signed for veterinary use and is licensed for use in dogs and cats.
Maropitant is effective at preventing emesis induced by apomor-
phine, ipecac (Sedlacek et al., 2008), chemotherapeutic agents (Rau
et al., 2010) and motion (Conder et al., 2008). Maropitant demon-
strated anti-nausiogenic eﬃcacy in dogs treated with cisplatin,
signiﬁcantly reducing VAS measurements for nausea when given
up to 19 h prior to or following IV cisplatin infusion (de la
Puente-Redondo et al., 2007). However, maropitant did not signiﬁ-
cantly change nausea scores comparedwith placebo in dogs receiving
doxorubicin treatment for cancer (Rau et al., 2010). Both of these
studies employed the VAS system of nausea assessment, which, as
mentioned earlier, is subjective and prone to wide inter- and intra-
observer variability. There is scope to explore the anti-nausiogenic
properties of maropitant further using more objective measures, if
these can be developed and validated.
CB1 receptor agonists
Cannabinoids (CB) are involved in the regulation of nausea. The
active ingredient of marijuana, delta-9-tetrahydrocannabinol (Δ9-
THC), has been found to be eﬃcacious in CINV (Tramer et al., 2001),
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leading to the development of a synthetic Δ9-THC, dronabinol, for
anti-emetic therapy. The CB1 receptor agonist HU-210 prevents the
development of lithium chloride-induced conditioned gaping; this
effect is reversible when rats are also treated with the cannabi-
noid (CB1) antagonist rimonobant (Parker and Mechoulam, 2003).
Pre-treatment of rats with the fatty acid amide hydrolase (FAAH)
inhibitor URB597, which prevents the breakdown of anandamide
(an endogenous cannabinoid), prior to lithium chloride-saccharin
pairing, attenuated the conditioned gaping response (Cross-Mellor
et al., 2007).
The site of action of CB1 agonists that account for their anti-
nausea properties is unknown. Conﬂicting evidence exists regarding
whether the location of target receptors is peripheral or central. Ad-
ministration of the peripherally restricted CB1 antagonist, AM6545,
failed to induce conditioned taste avoidance or conditioned gaping
in rats (Cluny et al., 2010), suggesting a central site of action of CB1
receptors in the development of conditioned gaping. However, sys-
temic administration of the CB1 antagonist AM251 increased
conditioned gaping in rats, whereas central administration into the
lateral and fourth ventricles did not potentiate conditioned gaping.
This suggests that nausea is mediated by peripheral CB1 receptors,
or central CB1 receptors located at a site other than the ventricles
(Limebeer et al., 2010). No data are available on cannabinoid re-
ceptors and nausea in companion animals.
Conclusions
The mechanisms controlling the genesis and processing of the
sensation of nausea are complex and poorly understood. Brain areas
involved in nausea perception are diverse, ﬁtting with nausea as a
complex perceptual experience. Currently available antiemetic thera-
pies are effective in both preventing and treating emesis, but nausea
is still a problem. Novel therapies that are more eﬃcacious for the
treatment and prevention of nausea would have clinical value.
Current behavioural measures of nausea are sub-optimal and iden-
tiﬁcation of a valid objective marker of nausea in the dog could
provide a useful tool for both research and clinical practice. Such
an objective marker would be of great value in the veterinary prac-
tice to identify circumstances where nausea is problematic, and to
increase the veterinarian’s awareness of nausea in the veterinary
patient population. An objective marker would also have applica-
tion in research to aid assessment of the eﬃcacy of new anti-
emetic compounds in preventing nausea, or to assess the nausiogenic
liability of novel chemical entities as an adverse effect. Nausea is a
neglected and potentially important area of companion animal med-
icine, primarily because the subjective nature of nausea makes it
challenging to detect clinically, therefore evaluation of the re-
sponse and choice of appropriate treatment is diﬃcult.
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